Bioasis Technologies Inc.
BIOAF · OTC
2/28/2022 | 2/28/2021 | 2/28/2020 | 2/28/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.33 | -0.58 | 0.18 |
| FCF Yield | -19.03% | 6.66% | -22.58% | -13.10% |
| EV / EBITDA | -5.44 | 54.71 | -3.32 | -4.87 |
| Quality | ||||
| ROIC | -621.16% | -59.88% | 494.98% | -781.49% |
| Gross Margin | -3,150.25% | 69.64% | 100.00% | 99.27% |
| Cash Conversion Ratio | 1.23 | 2.54 | 0.81 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -60.38% | 42.07% | 0.93% | 40.48% |
| Free Cash Flow Growth | -305.22% | 153.70% | -2.07% | 14.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | -5.99 | -0.09 | 0.28 |
| Interest Coverage | -7.37 | 0.00 | -110.74 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 501.62 | -540.75 | 8.04 | -34,898.30 |